Implications of the EU Falsified Medicines Directive for Dispensers, New Webinar Hosted by Xtalks

TORONTO, May 23, 2018 (Newswire.com) - The EU Falsified Medicines Directive requires that by February 9, 2019, pharmaceutical companies must serialise prescription medicines using a 2D barcode that contains the following information: product code, serial number, national reimbursement number (where required), batch number, and expiration date. This information must also be delivered in human-readable text on the medicine’s package.

Entities responsible for dispensing medication, namely hospitals and retail pharmacies, must be able to scan the 2D barcode at the point of dispensation (wherever that occurs in the facility) to verify that the pharmaceutical product is authentic and decommission it before distributing it to patients. In addition to affecting dispensers, the EU Falsified Medicines Directive legislation impacts many other pharma supply chain stakeholders, including market authorization holders, wholesalers, and parallel importers.

This 60-minute webinar upcoming on Wednesday, June 6, 2018, at 8 P.M. EDT (1 P.M. BST/UK) will focus primarily on the impact of EU Falsified Medicines Directive on dispensers, including doctors, hospitals, and pharmacies throughout Europe. Our experts will address the following questions:

• Where could the serialized medicines be scanned/dispensed?
• What hardware and software is needed, and how does it work? (And who pays for it?)
• What is the responsibility of the dispensing site regarding returned, recalled or withdrawn medicine?
• What do I need to know about parallel imported/distributed medicines?
• What is my role in interfacing with the European Medicines Verification System (EMVS) and the National Medicines Verification Systems (NMVS)?
• How is EU Falsified Medicines Directive different than the U.S Food and Drug Administration’s (FDA) Drug Supply Chain Security Act (DSCSA), and how do I avoid making the mistakes my North American counterparts made during DSCSA implementation?
• What is the potential for additional benefits beyond compliance, such as patient engagement?
• What medication is on the blacklist and what is on the whitelist or products that aren’t aggregated (i.e., which meds need to be scanned and which ones don’t? Will the dispenser need more resources?)

The featured speakers from OPTEL Group will also provide an update on the Oxford Hospital decommissioning pilot, which is extremely important for the European healthcare industry because it will help define how hospital management teams can use this requirement to improve patient safety.

The discussion including a Q&A with the audience will benefit professionals from hospitals, retail pharmacies and other organizations that are required to comply with EU FMD, including those in pharmacy, IT and compliance. Learn your responsibilities in detail with regard to the Falsified Medicines Directive before the legislation is applied.

For more information about this complimentary webinar visit: Implications of the EU Falsified Medicines Directive for Dispensers.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device community. Every year thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar.

Contact:

Nima Rajan

Tel: +1 (416) 977-6555 ext 352

Email: [email protected]

Source: Xtalks